Nuveen Asset Management Portfolio holdings
Nuveen Asset Management, founded in 1898 by John Nuveen and headquartered in Chicago, Illinois, is a leading global investment manager and subsidiary of TIAA, overseeing hundreds of billions in assets with a focus on fixed income, equities, and sustainable investing. Initially known for municipal bonds, Nuveen has expanded into a broad range of strategies, including mutual funds, ETFs, closed-end funds, and private capital solutions, serving institutional investors, financial advisors, and individuals. The firm emphasizes income-generating investments and ESG (environmental, social, governance) integration, leveraging its deep research capabilities and a century-long legacy in the bond market. With a strong presence in North America and growing international reach, Nuveen blends tradition with innovation to meet diverse client needs in the evolving investment landscape.
Top Buys
| 1 |
Advanced Micro Devices
AMD
|
$922M |
| 2 |
EOG Resources
EOG
|
$517M |
| 3 |
Mastercard
MA
|
$436M |
| 4 |
Las Vegas Sands
LVS
|
$385M |
| 5 |
Booking.com
BKNG
|
$382M |
Top Sells
| 1 |
Qualcomm
QCOM
|
$660M |
| 2 |
Morgan Stanley
MS
|
$519M |
| 3 |
PayPal
PYPL
|
$479M |
| 4 |
Meta Platforms (Facebook)
META
|
$478M |
| 5 |
Pfizer
PFE
|
$405M |
Sector Composition
| 1 | Technology | 24.82% |
| 2 | Financials | 12.45% |
| 3 | Healthcare | 12.44% |
| 4 | Consumer Discretionary | 11.85% |
| 5 | Industrials | 8.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2901
Q32 Bio
QTTB
$20.4M
| $664K | ﹤0.01% |
10,977
+784
| +8% | +$47.4K |
|
2902
The ONE Group
STKS
$85.1M
| $661K | ﹤0.01% |
61,728
+16,128
| +35% | +$173K |
|
2903
Cue Biopharma
CUE
$59.9M
| $659K | ﹤0.01% |
117,327
+34,006
| +41% | +$191K |
|
2904
Kinetik
KNTK
$2.58B
| $659K | ﹤0.01% |
19,932
+6,304
| +46% | +$208K |
|
2905
Ceco Environmental
CECO
$1.67B
| $654K | ﹤0.01% |
112,513
+1,483
| +1% | +$8.62K |
|
2906
EverCommerce
EVCM
$2.06B
| $654K | ﹤0.01% |
53,293
+11,137
| +26% | +$137K |
|
2907
Verastem
VSTM
$663M
| $651K | ﹤0.01% |
42,697
+634
| +2% | +$9.67K |
|
2908
MEI Pharma
MEIP
$139M
| $650K | ﹤0.01% |
18,049
+167
| +0.9% | +$6.01K |
|
2909
WELLS FARGO 7.5% NON CUMV PERP CONV
WFC.PRL
$4.91B
| – | – |
0
| – | -$752K |
|
2910
Enel Chile
ENIC
$5.12B
| $646K | ﹤0.01% |
408,572
+810
| +0.2% | +$1.28K |
|
2911
Dr. Reddy's Laboratories
RDY
$11.9B
| $644K | ﹤0.01% |
57,785
-2,161,240
| -97% | -$24.1M |
|
2912
Rimini Street
RMNI
$416M
| $638K | ﹤0.01% |
111,012
| – | – |
|
|
ENFN
2913
DELISTED
Enfusion, Inc.
ENFN
| $638K | ﹤0.01% |
50,118
+16,370
| +49% | +$208K |
|
2914
Unilever
UL
$158B
| $633K | ﹤0.01% |
13,892
-44,927
| -76% | -$2.05M |
|
2915
NI Holdings
NODK
$276M
| $629K | ﹤0.01% |
35,838
+356
| +1% | +$6.25K |
|
2916
Xoma
XOMA
$426M
| $627K | ﹤0.01% |
21,248
+8,762
| +70% | +$259K |
|
2917
Donegal Group Class A
DGICA
$689M
| $625K | ﹤0.01% |
46,170
+266
| +0.6% | +$3.6K |
|
2918
Passage Bio
PASG
$22.8M
| $622K | ﹤0.01% |
10,072
-2,630
| -21% | -$162K |
|
2919
CytomX Therapeutics
CTMX
$376M
| $621K | ﹤0.01% |
200,943
+1,413
| +0.7% | +$4.37K |
|
2920
uniQure
QURE
$985M
| $620K | ﹤0.01% |
35,847
+4,967
| +16% | +$85.9K |
|
2921
Pliant Therapeutics
PLRX
$114M
| $619K | ﹤0.01% |
81,824
-7,122
| -8% | -$53.9K |
|
2922
Apyx Medical
APYX
$74.1M
| $616K | ﹤0.01% |
85,991
| – | – |
|
2923
Lifetime Brands
LCUT
$97.2M
| $615K | ﹤0.01% |
45,820
+657
| +1% | +$8.82K |
|
|
KLRS
2924
Kalaris Therapeutics, Inc. Common Stock
KLRS
$86.4M
| $613K | ﹤0.01% |
3,514
+26
| +0.7% | +$4.54K |
|
|
DICE
2925
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $613K | ﹤0.01% |
32,044
+10,980
| +52% | +$210K |
|